ADXN · CIK 0001574232
Addex Therapeutics Ltd
Annual figures as reported, FY2016–FY2024. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
CHF 404K
▼ −74.9% vs FY2023
Net income
CHF 7.1M
▲ +166.8% vs FY2023
Free cash flow
−CHF 5.4M
▲ +32.8% vs FY2023
Diluted EPS
CHF 0.07
▲ +150.0% vs FY2023
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Operating marginNet margin
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Growth rates
compounding, annualizedRevenue CAGR
−48.3%
3y
−31.9%
5y
Share count change (split-adjusted)
+271.2%
5y
Key ratios
derived per fiscal year| Fiscal year | Op. margin | Net margin | FCF margin | ROE | ROA | Current ratio |
|---|---|---|---|---|---|---|
| FY2024 | −681.8% | 1746.0% | −1330.1% | 72.9% | 66.1% | 4.42× |
| FY2023 | −139.1% | −654.5% | −495.9% | −921.6% | −227.4% | 1.46× |
| FY2022 | −741.0% | −1462.6% | −1155.6% | −423.5% | −251.2% | 2.39× |
| FY2021 | −531.7% | −526.4% | −505.3% | −90.7% | −68.1% | 5.31× |
| FY2020 | −338.9% | −355.9% | −338.8% | −88.0% | −63.7% | 5.38× |
| FY2019 | −528.6% | −535.0% | −344.2% | −57.9% | −44.8% | 5.70× |
| FY2018 | −23.6% | −27.2% | 28.8% | −4.2% | −3.9% | 18.06× |
| FY2017 | — | — | — | −244.3% | — | — |
| FY2016 | — | — | — | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2024 | CHF 404K | — | −CHF 2.8M | CHF 7.1M | CHF 0.07 | −CHF 5.4M | CHF 1K | CHF 10.7M | CHF 1.0M | CHF 9.7M | CHF 3.3M | — |
| FY2023 | CHF 1.6M | — | −CHF 2.2M | −CHF 10.6M | −CHF 0.14 | −CHF 8.0M | CHF 7K | CHF 4.6M | CHF 3.5M | CHF 1.1M | CHF 3.9M | — |
| FY2022 | CHF 1.4M | — | −CHF 10.5M | −CHF 20.8M | −CHF 0.46 | −CHF 16.4M | CHF 581 | CHF 8.3M | CHF 3.4M | CHF 4.9M | CHF 7.0M | — |
| FY2021 | CHF 2.9M | — | −CHF 15.5M | −CHF 15.4M | −CHF 0.45 | −CHF 14.7M | CHF 32K | CHF 22.5M | CHF 5.6M | CHF 16.9M | CHF 20.5M | — |
| FY2020 | CHF 3.6M | — | −CHF 12.2M | −CHF 12.9M | −CHF 0.48 | −CHF 12.2M | CHF 59K | CHF 20.2M | CHF 5.6M | CHF 14.6M | CHF 18.7M | — |
| FY2019 | CHF 2.8M | — | −CHF 14.6M | −CHF 14.8M | −CHF 0.56 | −CHF 9.5M | CHF 28K | CHF 33.0M | CHF 7.5M | CHF 25.5M | CHF 31.5M | — |
| FY2018 | CHF 6.0M | — | −CHF 1.4M | −CHF 1.6M | — | CHF 1.8M | CHF 9K | CHF 42.2M | CHF 3.0M | CHF 39.2M | CHF 31.5M | — |
| FY2017 | — | — | −CHF 3.2M | −CHF 3.3M | — | −CHF 2.1M | CHF 697 | — | — | CHF 1.3M | CHF 2.6M | — |
| FY2016 | — | — | — | — | — | — | — | — | — | CHF 219K | CHF 1.4M | — |
Latest filings
the most recent regulatory filings6-KForeign issuer report2026-06-30 ↗6-KForeign issuer report2026-06-25 ↗6-KForeign issuer report2026-06-05 ↗20-FAnnual report (foreign issuer)2026-05-15 ↗6-KForeign issuer report2026-04-30 ↗NT 20-FSEC filing2026-04-30 ↗6-KForeign issuer report2026-04-29 ↗6-KForeign issuer report2026-04-23 ↗6-KForeign issuer report2026-04-21 ↗3OWNERSHIP DOCUMENT2026-03-25 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.